FDA Proposes Restrictions on GLP-1 Compounding Drugs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
- Positive Market Reaction: Following the FDA's proposal to restrict pharmacies from compounding GLP-1 drugs, shares of Eli Lilly and Novo Nordisk surged in early Thursday trading, reflecting investor confidence in their dominance in the weight loss drug market.
- Drug List Changes: The FDA's consideration to remove tirzepatide, semaglutide, and liraglutide from the 503B Bulk Drugs Substances List means pharmacies will no longer be able to compound these medications from bulk substances, potentially altering market supply dynamics.
- Clinical Need Assessment: The FDA noted that there is no clinical need for these three medications to remain on the list, which could help protect patients and maintain the integrity of the drug approval process, thereby impacting drug market availability and pricing strategies.
- Industry Outlook: With the FDA's proposal, the competitive landscape for Eli Lilly's Zepbound and Mounjaro, as well as Novo's Wegovy and Ozempic, may shift, prompting investors to monitor future market dynamics and company financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 934.600
Low
950.00
Averages
1192
High
1500
Current: 934.600
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
GLP-1 Drugs Spark Hair Loss Trend in Beauty Market
- Surge in Market Demand: According to Gallup, the use of GLP-1 drugs has more than doubled since early 2024, with nearly 13% of U.S. adults currently using them, leading to increased demand for hair treatment products as the user base expands.
- Increased Consumer Spending: Research firm Circana reports that GLP-1 households spend approximately 30% more on beauty products than non-GLP-1 households, indicating that hair loss solutions have become a significant growth segment in the beauty industry amid ongoing consumer stress post-pandemic.
- Brand Innovation Response: Redken has launched an entire Acidic Grow Full System specifically designed for GLP-1 users, addressing their unique hair care needs and showcasing the brand's responsiveness to emerging market opportunities.
- Long-term Customer Loyalty: As hair treatment products often take months to show results, GLP-1 users are expected to exhibit high brand loyalty, providing ongoing commercial opportunities for companies in the hair care sector as the market continues to grow.
See More
Eli Lilly's Foundayo Struggles Against Wegovy in Weight Loss Market
- Market Acceptance Analysis: Eli Lilly's oral GLP-1 drug Foundayo recorded 5,612 prescriptions in its third week, indicating low market acceptance, especially compared to Novo Nordisk's oral Wegovy, which had over 134,000 prescriptions in the same period, highlighting Wegovy's first-mover advantage.
- Patient Treatment Status: As of April 30, Eli Lilly executives reported that over 20,000 patients have been treated with Foundayo; however, this figure appears weak compared to Wegovy's market performance, potentially leading to negative investor sentiment.
- Future Expectations: RBC Capital Markets analyst Trung Huynh expects Foundayo to exceed 90,000 prescriptions by week 12 to stay on track for its annual sales expectation of about $1.4 billion, and achieving this target will directly impact Eli Lilly's market performance and investor confidence.
- Financial Outlook: Eli Lilly projects revenues of $82 billion to $85 billion by 2026, with non-GAAP EPS expected between $35.50 and $37, positioning Foundayo's launch as a crucial component for achieving these targets, despite its current underwhelming market performance.
See More
Apple's Strong Earnings Propel Market to New Highs
- Market Highs: The S&P 500 reached a new intra-day high on Friday, driven by a more than 4% rise in Apple shares, indicating the positive impact of its strong performance and reinforcing the comeback of the 'Magnificent Seven'.
- Apple's Impressive Earnings: Apple's second-quarter revenue surged 17% to $111.2 billion, surpassing the $109.7 billion estimate, with strong guidance boosting investor confidence and suggesting further stock price increases ahead.
- Eli Lilly's Strong Performance: Eli Lilly's shares rose another 3% following a nearly 10% rally post-earnings, with a remarkable 56% year-over-year revenue increase to $19.8 billion, leading Jim Cramer to assert that selling the stock would be premature.
- Investor Strategy Advice: Jim Cramer advises investors to tune into Apple's earnings call, emphasizing a strategy of holding rather than trading, as he believes there is significant room for the stock to grow, reflecting optimism about its future prospects.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
GLP-1 Drugs Spark Hair Loss Trend in Beauty Market
- Surge in Market Demand: According to Gallup, the use of GLP-1 drugs has more than doubled since early 2024, with nearly 13% of U.S. adults currently using them, leading to increased demand for hair treatment products as the user base expands.
- Increased Consumer Spending: Research firm Circana reports that GLP-1 households spend approximately 30% more on beauty products than non-GLP-1 households, indicating that hair loss solutions have become a significant growth segment in the beauty industry amid ongoing consumer stress post-pandemic.
- Brand Innovation Response: Redken has launched an entire Acidic Grow Full System specifically designed for GLP-1 users, addressing their unique hair care needs and showcasing the brand's responsiveness to emerging market opportunities.
- Long-term Customer Loyalty: As hair treatment products often take months to show results, GLP-1 users are expected to exhibit high brand loyalty, providing ongoing commercial opportunities for companies in the hair care sector as the market continues to grow.
See More
Eli Lilly's Foundayo Struggles Against Wegovy in Weight Loss Market
- Market Acceptance Analysis: Eli Lilly's oral GLP-1 drug Foundayo recorded 5,612 prescriptions in its third week, indicating low market acceptance, especially compared to Novo Nordisk's oral Wegovy, which had over 134,000 prescriptions in the same period, highlighting Wegovy's first-mover advantage.
- Patient Treatment Status: As of April 30, Eli Lilly executives reported that over 20,000 patients have been treated with Foundayo; however, this figure appears weak compared to Wegovy's market performance, potentially leading to negative investor sentiment.
- Future Expectations: RBC Capital Markets analyst Trung Huynh expects Foundayo to exceed 90,000 prescriptions by week 12 to stay on track for its annual sales expectation of about $1.4 billion, and achieving this target will directly impact Eli Lilly's market performance and investor confidence.
- Financial Outlook: Eli Lilly projects revenues of $82 billion to $85 billion by 2026, with non-GAAP EPS expected between $35.50 and $37, positioning Foundayo's launch as a crucial component for achieving these targets, despite its current underwhelming market performance.
See More
Apple's Strong Earnings Propel Market to New Highs
- Market Highs: The S&P 500 reached a new intra-day high on Friday, driven by a more than 4% rise in Apple shares, indicating the positive impact of its strong performance and reinforcing the comeback of the 'Magnificent Seven'.
- Apple's Impressive Earnings: Apple's second-quarter revenue surged 17% to $111.2 billion, surpassing the $109.7 billion estimate, with strong guidance boosting investor confidence and suggesting further stock price increases ahead.
- Eli Lilly's Strong Performance: Eli Lilly's shares rose another 3% following a nearly 10% rally post-earnings, with a remarkable 56% year-over-year revenue increase to $19.8 billion, leading Jim Cramer to assert that selling the stock would be premature.
- Investor Strategy Advice: Jim Cramer advises investors to tune into Apple's earnings call, emphasizing a strategy of holding rather than trading, as he believes there is significant room for the stock to grow, reflecting optimism about its future prospects.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
